268 related articles for article (PubMed ID: 21502425)
1. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
2. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Zamora L; Xandri M; Garcia O; Marcé S; Xicoy B; Granada I; Navarro JT; Millá F
Am J Clin Pathol; 2012 Apr; 137(4):677-8. PubMed ID: 22431549
[No Abstract] [Full Text] [Related]
3. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
4. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
5. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
6. [A case report of myelodysplastic/myeloproliferative disease unclassifiable with karyotype aberration of trisomy 8 and JAK2 mutation].
Liu K; Ying CX; Chen XD; Zhou XY; Guo KY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1139-43. PubMed ID: 23114135
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
8. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
9. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
[TBL] [Abstract][Full Text] [Related]
10. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
[TBL] [Abstract][Full Text] [Related]
11. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
12. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status.
Vadikolia CM; Tsatalas C; Anagnostopoulos K; Trypsianis G; Pantelidou D; Bazdiara I; Anastasiadis A; Spanoudakis E; Kotsianidis I; Margaritis D; Kortsaris A; Bourikas G
Acta Haematol; 2011; 126(1):54-62. PubMed ID: 21474922
[TBL] [Abstract][Full Text] [Related]
14. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.
Campbell PJ; Baxter EJ; Beer PA; Scott LM; Bench AJ; Huntly BJ; Erber WN; Kusec R; Larsen TS; Giraudier S; Le Bousse-Kerdilès MC; Griesshammer M; Reilly JT; Cheung BY; Harrison CN; Green AR
Blood; 2006 Nov; 108(10):3548-55. PubMed ID: 16873677
[TBL] [Abstract][Full Text] [Related]
15. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
16. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
17. Karyotype and molecular cytogenetic studies in polycythemia vera.
Andrieux JL; Demory JL
Curr Hematol Rep; 2005 May; 4(3):224-9. PubMed ID: 15865876
[TBL] [Abstract][Full Text] [Related]
18. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
Gangat N; Tefferi A; Thanarajasingam G; Patnaik M; Schwager S; Ketterling R; Wolanskyj AP
Eur J Haematol; 2009 Jul; 83(1):17-21. PubMed ID: 19236446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]